| |
PWS
|
AS
|
|---|
|
Medication use
|
|
Growth hormone
|
68.0%
|
0%
|
|
Anticonvulsant
|
8.0%
|
73.7%
|
|
Genetic subtype
|
|
Deletion
|
24.0%
|
47.4%
|
|
UPD
|
64.0%
|
15.8%
|
|
Imprinting centre defect
|
8.0%
|
0%
|
|
Abnormal methylationa
|
4.0%
|
5.2%
|
|
UBE3A mutation
|
NA
|
31.6%
|
- aMethylation analysis confirmed PWS or AS diagnosis, but further analysis to confirm specific subtypes had not been undertaken